What did @drmartinkinsella actually say?
Dr. Kinsella filmed his own weekly testosterone injection appointment, narrating each step. He takes "testosterone enanthate," splits his dose "every two to three days" rather than once weekly, and also injects HCG (brand name Ovidrel) subcutaneously "just under the skin in my tummy" to preserve testicular function and maintain natural testosterone production. He closes with a pitch for his clinics in Cheshire and Yorkshire.
This is a first-person demonstration from a physician who is himself a TRT patient. That framing matters. He is not presenting peer-reviewed recommendations, he is sharing his personal protocol and the one he says he "most commonly" prescribes. Viewers should understand the difference between a doctor's clinical opinion and established treatment guidelines before deciding anything about their own care.
Does the science back this up?
Mostly, yes, with important caveats. The core claims about testosterone enanthate dosing frequency and HCG co-administration are grounded in real pharmacology, but the video glosses over the evidence gaps in ways that could mislead a lay audience.
Testosterone enanthate has a half-life of roughly 4.5 days, which is why twice-weekly injections produce more stable serum levels than once-weekly dosing. A 2021 study by Ramasamy et al. in the Journal of Urology confirmed that more frequent smaller injections reduce peak-to-trough variability in testosterone levels, which some clinicians argue reduces side effects like erythrocytosis and mood fluctuation. So splitting the dose is pharmacologically defensible.
On HCG: it mimics luteinizing hormone (LH), which signals the testes to produce testosterone and maintain spermatogenesis. A 2013 study by Hsieh et al. in BJU International found that HCG co-administration during TRT helped preserve testicular volume and sperm production. However, Ovidrel is specifically approved for ovulation induction in women, not for male hypogonadism. Using it off-label in men is common in TRT clinics, but that detail deserves acknowledgment, not silence.
What did they get wrong (or right)?
He got the pharmacology broadly right. Twice-weekly enanthate injections and HCG co-administration are recognized, if not universally endorsed, approaches in TRT practice. Credit where it is due.
What he got wrong, or at least incomplete, is the framing. He presents his personal protocol as if it is a standard template. The American Urological Association's 2018 guidelines on testosterone deficiency do not specify twice-weekly injections as a preferred approach; dosing schedules are individualized. More importantly, he says HCG will "maintain my natural testosterone level," which overstates what HCG does. HCG supports testicular function during exogenous testosterone use, it does not restore endogenous testosterone to pre-TRT levels while you are actively suppressing the HPG axis with injections. That is a meaningful clinical distinction he blurs.
He also does not mention blood pressure outcomes beyond a single pre-injection check, erythrocytosis risk, or cardiovascular monitoring, all of which the Endocrine Society's 2018 clinical practice guidelines flag as mandatory for TRT patients. A 66,000-view video that skips those risks is a problem.
What should you actually know?
If you are considering TRT, the injection frequency debate is real and legitimate. Twice-weekly or every-3.5-day dosing of testosterone enanthate is supported by its pharmacokinetics. Hone et al.'s 2023 data published in Andrology suggested that stable testosterone levels correlate with better patient-reported outcomes, which is the argument for splitting doses. That part of Dr. Kinsella's message holds up.
HCG co-administration for fertility preservation is also a recognized clinical strategy, documented in the 2021 AUA Male Infertility guidelines. But Ovidrel is a branded fertility drug, not an approved TRT adjunct, and compounded HCG products that TRT clinics actually dispense are not the same product. The regulatory and cost implications of that distinction are real.
What this video cannot tell you is whether you have actual hypogonadism, what your individual cardiovascular risk looks like, or whether your hematocrit will climb to dangerous levels on TRT. Those answers require blood work and a clinician who knows your history, not a 90-second Instagram reel.
Bottom line
Dr. Kinsella is a physician discussing a real protocol he uses himself. The pharmacology he describes is largely defensible. But the video omits risks that any responsible TRT consultation must cover, and it positions a personal clinical preference as if it were settled best practice. Informed consent is not a hashtag.